The boy who cried wolf

In the last 50 weeks, the value of my SMSF has risen by 180%.  During that period Harvett has been a constant critic, but like the boy who cried wolf, he lost credibility.  If capable of dispassionate analysis, Harvett could have made a great deal of money for his family during those 50 weeks.

Today, H has dissed a story about GK's successful self-treatment and in the process, again demonstrated his inability to see the big picture.  It is irrelevant that Idronoxil was invented more than 20 years ago and is off-patent, because to be effective, it needs to be dissolved in a lipophilic suppository base. Noxopharm has that covered in its patent applications.

No competitor is using off-patent Idronoxil in oral or intravenous form for a simple reason - it will not work.  Dr. Kelly saved his life, and potentially millions more, when he invented a way to overcome Phase 2 metabolism.  This has led to a series of unexpected discoveries about the mechanism of action of Idronoxil, each protected by patent applications.  


As an investor, it is highly relevant to me that Graham Kelly is healthy 7 years after being given two months to live.  That news will never be 'old', especially now that the Phase 2 DARRT trial will use high, repeat doses of NOX66 that led to his incredible recovery.